Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Cash & Equivalents (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Cash & Equivalents readings, the most recent being $17.3 million for Q4 2017.

  • On a quarterly basis, Cash & Equivalents rose 1449.06% to $17.3 million in Q4 2017 year-over-year; TTM through Dec 2017 was $17.3 million, a 1449.06% increase, with the full-year FY2017 number at $17.3 million, up 1449.06% from a year prior.
  • Cash & Equivalents hit $17.3 million in Q4 2017 for Eledon Pharmaceuticals, down from $19.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $105.5 million in Q3 2014 to a low of $1.1 million in Q4 2016.
  • Median Cash & Equivalents over the past 5 years was $23.6 million (2013), compared with a mean of $36.3 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 95.35% in 2016 and later surged 1449.06% in 2017.
  • Eledon Pharmaceuticals' Cash & Equivalents stood at $31.8 million in 2013, then skyrocketed by 231.48% to $105.3 million in 2014, then tumbled by 77.18% to $24.0 million in 2015, then crashed by 95.35% to $1.1 million in 2016, then surged by 1449.06% to $17.3 million in 2017.
  • The last three reported values for Cash & Equivalents were $17.3 million (Q4 2017), $19.2 million (Q3 2017), and $22.6 million (Q2 2017) per Business Quant data.